Bendazac
产品说明书
 |
同义名 : | AF 983; bendazolic acid; Versus; Bindazac |
| CAS号 : | 20187-55-7 | |
| 货号 : | A625280 | |
| 分子式 : | C16H14N2O3 | |
| 纯度 : | 98% | |
| 分子量 : | 282.29 | |
| MDL号 : | MFCD00866158 | |
| 存储条件： |
Pure form Keep in dark place,Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Bendazac is an oxyacetic acid with anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties, but its principal effect is to inhibit the denaturation of proteins[1]. Bendazac is an anti-inflammatory agent endowed with protein antidenaturant properties effective for various inflammatory skin conditions. Bendazac has been shown to be a strong reacting substrate in a chemical oxidizing system, which mimics a physiological pathway of hydroxy radical generation. Moreover, by means of a rapid and sensitive flow cytometric method able to determine reactive oxygen intermediate production, bendazac and its 5-hydroxy derivative were shown to inhibit oxidative burst activation in polymorphonuclear neutrophil leukocytes (PMNLs)[2]. Bendazac (bendazac L-lysine and sodium) inhibits the early stages of protein glycation, as well as the formation of fluorescent advanced glycation products. Bendazac lysine (20 mM) proved to be more effective in inhibiting fluorescence development (67% inhibition) that the corresponding sodium salt (35% inhibition). About 40% inhibition was produced with either bendazac lysine or sodium salt bendazac clearly inhibits glycation of human lens crystallins[3]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
3.54mL 0.71mL 0.35mL |
17.71mL 3.54mL 1.77mL |
35.42mL 7.08mL 3.54mL |
| 参考文献 |
|---|